Dr Vaishampayan on Patient Considerations When Choosing Between FDA-Approved Therapies in nmCRPC

Ulka Nitin Vaishampayan, MBBS, discusses patient factors to consider when choosing between apalutamide, enzalutamide, and darolutamide for the treatment of patients with non-metastatic castration resistant prostate cancer.

Related Keywords

Michigan ,United States ,Ulka Nitin Vaishampayan ,Phasei Program ,Rogel Cancer Center ,University Of Michigan ,Onclive Tv ,Nmcrpc ,Non Metastatic Castration Resistant Prostate Cancer ,